




Supplementary Figure S6. Distribution of individual JAK and TNF inhibitors across molecular clusters in b/tsDMARD-naïve RA patients. – (A) Baseline expression of the *ex vivo* JAKi protein signature in b/tsDMARD-naïve RA patients initiating JAKi therapy, with molecular cluster assignment and the individual JAK inhibitor subsequently received shown as top annotations. (B) Relative distribution of baricitinib, tofacitinib, upadacitinib, and filgotinib within JAKi molecular clusters C1 and C2. The distribution of baricitinib versus all other JAKi agents did not significantly differ between clusters (Fisher’s exact test, p-value=0.409). (C) Baseline expression of the *ex vivo* TNFi protein signature in b/tsDMARD-naïve RA patients initiating TNFi therapy, with molecular cluster assignment and the individual TNF inhibitor subsequently received shown as top annotations. (D) Relative distribution of adalimumab, etanercept, infliximab, certolizumab, and golimumab within TNFi molecular clusters C1 and C2. The distribution of etanercept versus all other TNFi agents did not significantly differ between clusters (Fisher’s exact test, p-value=1.000).